Contraindicated in:
- Hypersensitivity to sumatriptan or latex (needle shield of prefilled syringe contains rubber [latex derivative])
- Ischemic heart disease or signs and symptoms of ischemic heart disease, Prinzmetal's angina, or uncontrolled hypertension
- Stroke or transient ischemic attack
- Peripheral vascular disease (including, but not limited to, ischemic bowel disease)
- Concurrent MAO inhibitor therapy
- Hemiplegic or basilar migraine
- Concurrent use of (within 24 hr) ergotamine-containing or ergot-type drugs or other 5HT1 agonists
- Severe hepatic impairment.
Use Cautiously in:
- OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk
- Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant
- Rep: Women of reproductive potential
- Pedi: Safety and effectiveness not established in children
- Geri: ↑risk of cardiovascular complications in older adults.
Exercise Extreme Caution in:
- Cardiovascular risk factors (hypertension, hypercholesterolemia, smoking, obesity, diabetes, family history, menopausal women or men >40 yr); use only if cardiovascular status has been evaluated and determined to be safe and 1st dose is administered under supervision.
CV: angina, chest pressure, chest tightness, coronary vasospasm, ECG changes, MI, transient hypertension.
Derm: tingling, warm sensation, burning sensation, cool sensation, flushing.
EENT: alterations in vision, nasal sinus discomfort, throat discomfort.
GI: abdominal discomfort, dysphagia.
Local: injection site reaction.
MS: jaw discomfort, muscle cramps, myalgia, neck pain, neck stiffness.
Neuro: dizziness, vertigo, anxiety, drowsiness, fatigue, feeling of heaviness, feeling of tightness, headache, malaise, numbness, tight feeling in head, weakness.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Imitrex, Imitrex STATdose, Onzetra Xsail, Tosymra, Zembrace SymTouch
Therapeutic Classification: vascular headache suppressants
Pharmacologic Classification: five ht1 agonists
Absorption: Well absorbed (97%) after SUBQ administration. Absorption after oral administration is incomplete and significant amounts undergo substantial hepatic metabolism, resulting in poor bioavailability (14%). Well absorbed after intranasal administration.
Distribution: Well distributed to tissues.
Metabolism/Excretion: Mostly metabolized (80%) by the liver.
Half-life: 2 hr.
2 hr. Do not administer 2nd dose if no relief was provided by 1st dose without consulting health care professional.